Results 141 to 150 of about 68,908 (269)

Risperidone Controlled Release Microspheres Based on Poly(Lactic Acid)-Poly(Propylene Adipate) Novel Polymer Blends Appropriate for Long Acting Injectable Formulations [PDF]

, 2018
Stavroula Nanaki, Panagiotis Barmpalexis, Alexandros Iatrou, Evi Christodoulou, Margaritis Kostoglou, Dimitrios Ν. Bikiaris   +5 more
openalex   +1 more source

COVID‐19 Infection Changed P300 Latency in Patients With Psychosis: A Retrospective Cohort Study

Health Science Reports, Volume 9, Issue 1, January 2026.
ABSTRACT Background and Aims The COVID‐19 pandemic raises concerns about neurological impacts on individuals with mental health conditions, particularly cognitive function. P300 event‐related potential (ERP) latency is a validated neurophysiological marker of attention and working memory.
Xiaofeng Jiang, Shunqi Qiu, Weiwei Wang, Siwen Xu, Shengpang Wang   +4 more
wiley   +1 more source

Comparative study of the efficacy and safety between blonanserin and risperidone for the treatment of schizophrenia in Chinese patients: A double-blind, parallel-group multicenter randomized trial

, 2015
Huafang Li, Chen Yao, Jianguo Shi, Fude Yang, Shuguang Qi, Lili Wang, Honggeng Zhang, Jie Li, Chuanyue Wang, Chuansheng Wang, Cui Liu, Lehua Li, Qiang Wang, Keqing Li, Xiaoyan Luo, Niufan Gu   +15 more
openalex   +1 more source

Risperidone long‐acting injection: a 6‐year mirror‐image study of healthcare resource use [PDF]

, 2009
David Taylor, Catrin Fischetti, Anna Sparshatt, Arwel Thomas, Delia Bishara, Victoria Cornelius   +5 more
openalex   +1 more source

Comparison of Side Effects Between 3‐Monthly and 1‐Monthly Paliperidone Palmitate Formulations in Patients With Schizophrenia

Human Psychopharmacology: Clinical and Experimental, Volume 41, Issue 1, January 2026.
ABSTRACT Background The paliperidone palmitate 3‐month (PP3M) formulation offers an extended dosing interval compared to the 1‐month (PP1M) formulation. However, data on the comparative side effect profiles of PP1M versus PP3M in real‐world settings remain limited.
Erkan Kuru, Ilker Ozdemir, Bengu Yucens, M. Hakan Türkçapar   +3 more
wiley   +1 more source

Clinical utility of the risperidone formulations in the management of schizophrenia

Neuropsychiatric Disease and Treatment, 2011
Vishal Madaan1, Durga P Bestha2, Venkata Kolli2, Saurabh Jauhari2, Roger C Burket1 1University of Virginia Health System, Charlottesville, VA, USA; 2Creighton University Medical Center, Omaha, NE, USA Abstract: Risperidone is one of the early second ...
Madaan V, Bestha DP, Kolli VB, Jauhari S, Burket RC   +4 more
doaj  

Effects of Atypical Neuroleptics on Sustained Attention Deficits in Schizophrenia A Trial of Risperidone Versus Haloperidol [PDF]

, 2000
Shi K. Liu
openalex   +1 more source

A Systematic Review of the Parkinson's Foundation Hospital Care Recommendations

Movement Disorders Clinical Practice, Volume 13, Issue 1, Page 29-43, January 2026.
Abstract Background People with Parkinson's disease (PwP) face increased risks of complications and longer hospital stays compared to the general population. Four major factors contribute to increased morbidity and mortality during hospitalization: medication timing errors, administration of harmful medications, restricted mobility, and dysphagia ...
Ariane Veilleux Carpentier, Irene A. Malaty, Peter A. LeWitt, Hooman Azmi, Anne Brooks, Edward Pollak, Ellen L. Air, Heather Simpson, Jaime Thomas, Florian P. Thomas, Lisa Cocoziello, Sheera Rosenfeld, Michael S. Okun   +12 more
wiley   +1 more source

Peer Review #1 of "Association between gonadal hormones and osteoporosis in schizophrenia patients undergoing risperidone monotherapy: a cross-sectional study (v0.1)"

, 2021
Yi Chen, Yaoyao Zhang, Kaili Fan, Weiqian Xu, Chao Teng, Shuangshuang Wang, Wei Tang, Xiaomin Zhu, M Liang, B Zhang, L Deng, R Xu, H Wu, J Chen, J Cui, H Liu, J Shao, D Xu, Y Wang, Z Fei, J Wei, W Lu, C Wang, R He, Y Tan, Y Fan, Y Ning, R Cassidy, J Soares, X Huang, X Zhang, G Li, L Thabane, A Papaioannou, G Ioannidis, M Levine, J Adachi, M Crews, O Howes, P Stpnicki, M Kondej, A Kaczor, C Andrade, B Stubbs, F Gaughran, A Mitchell, De Hert, M Farmer, R Soundy, A Rosenbaum, S Vancampfort, D, U Halbreich, B Kinon, J Gilmore, L Kahn, J Peuskens, L Pani, J Detraux, De Hert, M, K Okita, N Kanahara, M Nishimura, T Yoshida, N Yasui-Furukori, T Niitsu, T Yoshida, M Ishikawa, H Kimura, F Nomura, M Iyo, W Li, H Zhu, H Xu, B Zhang, S Huang, T Chopko, C Lindsley, N Mohamad, I Soelaiman, K Chin, J Bishop, L Rubin, J Reilly, M Pavuluri, J Sweeney, D Becker, O Liver, R Mester, M Rapoport, A Weizman, M Weiss, B Stubbs, De Hert, M Sepehry, A Correll, C Mitchell, A Soundy, A Detraux   +99 more
openalex   +2 more sources

Piperazine Derivatives: A Privileged Scaffold in Modern Synthesis and Medicinal Chemistry

ChemistryOpen, Volume 15, Issue 1, January 2026.
Piperazine‐based bioactive molecules represent a versatile class of compounds with broad therapeutic potential. Structural modification of the piperazine scaffold governs key structure–activity relationships, enabling antibacterial, antifungal, antitumor, neuroactive, and anti‐inflammatory activities.
Assel Ten, Raushan Koizhaiganova, Dilnaz Bissenbay, Bagila Tursynova, Zhanar Zhaxibayeva, Valentina Yu   +5 more
wiley   +1 more source